Affimed Presents Preclinical Data Showing that Addition of an Innate Cell Engager to NK and CAR-NK Cells Improves Tumor Cytotoxicity of Both Cell Types at the 38th Annual Meeting of the Society for Immunotherapy of Cancer

Addition of Affimed’s innate cell engager improves cytotoxicity of natural killer cells and CAR-NK cellsNK cells with ICE® show at least comparable anti-tumor cell efficacy to CAR-NK cells with...

Related Keywords

Russia ,Texas ,United States ,New York ,Ukraine ,Germany ,Mannheim ,Baden Wüberg ,Mary Beth Sandin ,Thomas Grunwald ,Jan Schmollinger ,Ivica Fucek ,Paul Franz ,Joe Fischer ,Sonya Ioana Ciulean ,Arndt Schottelius ,Christian Breunig ,Thea Eichenberg ,Julia Uhlig ,Jens Pahl ,Christoph Bach ,Joachim Koch ,Michael Albers ,Stephan Fricke ,Alexander Fudukidis ,Society For Immunotherapy Of Cancer ,University Of Texas Md Anderson Cancer Center ,San Diego Convention Center ,Fraunhofer Institute For Cell Therapy ,Fraunhofer Institute ,Cell Therapy ,Chief Scientific Officer ,Innate Cell Engagers ,Presentation Time ,Exhibit Halls ,San Diego Convention ,Cancer Center ,Markets ,